Bloom Burton Reaffirms Accumulate Rating for Knight Therapeutics Inc (GUD)
Other equities research analysts have also issued research reports about the company. CIBC upped their price target on Knight Therapeutics from C$9.50 to C$9.80 in a research report on Friday. TD Securities upped their target price on Knight Therapeutics from C$10.00 to C$11.00 and gave the company a buy rating in a research report on Friday. Finally, Scotiabank cut their target price on Knight Therapeutics from C$10.00 to C$9.50 and set an outperform rating on the stock in a research report on Friday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of Buy and an average price target of C$9.83.
Knight Therapeutics (TSE:GUD) opened at 9.64 on Thursday. Knight Therapeutics has a 1-year low of $5.89 and a 1-year high of $9.82. The firm has a 50-day moving average price of $9.19 and a 200-day moving average price of $8.63. The company has a market capitalization of $1.28 billion and a P/E ratio of 67.89.
About Knight Therapeutics
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.